Insider Transactions in Q4 2024 at Denali Therapeutics Inc. (DNLI)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2024
|
Steve E. Krognes Director |
SELL
Open market or private sale
|
Direct |
30,000
-50.76%
|
$600,000
$20.25 P/Share
|
|
Dec 27
2024
|
Alexander O. Schuth COFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
6,708
+3.16%
|
$33,540
$5.28 P/Share
|
|
Nov 25
2024
|
Carole Ho Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,845
+11.55%
|
$0
$0.68 P/Share
|
|
Nov 22
2024
|
Alexander O. Schuth COFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
20,516
+9.36%
|
$0
$0.68 P/Share
|
|
Nov 11
2024
|
David P Schenkein Director |
SELL
Open market or private sale
|
Direct |
59,441
-58.66%
|
$1,902,112
$32.48 P/Share
|
|
Nov 11
2024
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
47,165
+40.72%
|
$848,970
$18.0 P/Share
|
|
Nov 07
2024
|
Alexander O. Schuth COFO and Secretary |
SELL
Open market or private sale
|
Direct |
15,558
-2.72%
|
$466,740
$30.56 P/Share
|
|
Nov 07
2024
|
Alexander O. Schuth COFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
15,558
+7.44%
|
$77,790
$5.28 P/Share
|
|
Nov 07
2024
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
1,020
-0.91%
|
$30,600
$30.0 P/Share
|
|
Nov 01
2024
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
3,080
-2.67%
|
$83,160
$27.07 P/Share
|
|
Oct 18
2024
|
Ryan J. Watts President and CEO |
SELL
Open market or private sale
|
Direct |
40,000
-14.5%
|
$1,080,000
$27.69 P/Share
|
|
Oct 18
2024
|
Ryan J. Watts President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+12.67%
|
$0
$0.68 P/Share
|